Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (141-150 of 194) with videos related to

Pageof 20
Sort By:
Bulletin Du Cancer|September 30, 1998
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord]P Huc, S Block, D Carlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)A Awada, I N Bondarenko, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2005
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyR Arriagada, M G Lê, M Spielmann, et al.
Gynecologie, Obstetrique & Fertilite|May 17, 2005
[Sentinel node biopsy without systematic axillary dissection: study about 1000 procedures]S Giard, M-P Chauvet, J-L Houpeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancerT Skovsgaard, N G Davidson, M J Piccart, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trialJ Bonneterre, L Mauriac, B Weber, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumorsJ P Peyrat, J Bonneterre, P H Vennin, et al.
The International Journal of Biological Markers|July 5, 2003
Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patientsM Hebbar, M A Krzewinski-Recchi, L Hornez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1990
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapyJ Bonneterre, B Chevallier, R Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative GroupP F Conte, J Latreille, L Mauriac, et al.
Pageof 20

Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|September 30, 1998
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord]P Huc, S Block, D Carlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)A Awada, I N Bondarenko, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2005
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyR Arriagada, M G Lê, M Spielmann, et al.
Gynecologie, Obstetrique & Fertilite|May 17, 2005
[Sentinel node biopsy without systematic axillary dissection: study about 1000 procedures]S Giard, M-P Chauvet, J-L Houpeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancerT Skovsgaard, N G Davidson, M J Piccart, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trialJ Bonneterre, L Mauriac, B Weber, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumorsJ P Peyrat, J Bonneterre, P H Vennin, et al.
The International Journal of Biological Markers|July 5, 2003
Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patientsM Hebbar, M A Krzewinski-Recchi, L Hornez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1990
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapyJ Bonneterre, B Chevallier, R Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative GroupP F Conte, J Latreille, L Mauriac, et al.
Pageof 20